IONS Q4 2020 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$290M-41.2% YoY

Gross Profit

$287M98.9% margin

Operating Income

-$23M-7.8% margin

Net Income

-$340M-117.2% margin

EPS (Diluted)

$-2.43

QoQ Revenue Growth

+81.3%

Cash Flow

Operating Cash Flow

$98M

Free Cash Flow

$91M

Stock-Based Comp.

$95M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$1.6B

Stockholders' Equity

$743M

Cash & Equivalents

$398M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$290M	$494M	-41.2%
Gross Profit	$287M	$493M	-41.8%
Operating Income	-$23M	$261M	-108.7%
Net Income	-$340M	$184M	-284.5%

Revenue Segments

Research and Development Revenue Under Collaborative Agreements

$195M43%

Spinraza Royalties

$141M31%

Commercial

$96M21%

Product

$19M4%

Licensing and Other Royalties

$2M0%